BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

7406

532296

GLENMARK

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GLENMARK PHARMACEUTICALS performance

Today’s low

Today’s high

₹ 1372.00 ₹ 1406.60
₹ 1381.20

52 week low

52 week high

₹ 985.20 ₹ 1830.95
₹ 1381.20

Open Price

₹ 1384.40

Prev. Close

₹ 1384.40

Volume (Shares)

694501.00

Total traded value

₹ 9592.44

Upper Circuit

₹ 1522.80

Lower Circuit

₹ 1246.00

info

GLENMARK PHARMACEUTICALS Share Price Update

As of the latest trading session, GLENMARK PHARMACEUTICALS share price is currently at ₹ 1381.2, which is down by ₹ -3.20 from its previous closing. Today, the stock has fluctuated between ₹ 1372.00 and ₹ 1406.60. Over the past year, GLENMARK PHARMACEUTICALS has achieved a return of 30.64 %. In the last month alone, the return has been -8.48 %. Read More...

GLENMARK PHARMACEUTICALS fundamentals


  • Market cap (Cr)

    38,975.83

  • P/E Ratio (TTM)

    6.41

  • Beta

    0.96

  • Book Value / share

    848.58

  • Return on equity

    6.98%

  • EPS (TTM)

    81.65

  • Dividend yield

    0.18%

  • Net profit/quarter (Cr)

    413.80

info icon alternate text
  • Market cap (Cr)

    38,871.42

  • P/E Ratio (TTM)

    6.41

  • Beta

    0.91

  • Book Value / share

    848.58

  • Return on equity

    6.98%

  • EPS (TTM)

    81.65

  • Dividend yield

    0.18%

  • Net profit/quarter (Cr)

    413.80

info icon alternate text

GLENMARK PHARMACEUTICALS Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 2208.84
Operating Expense 1820.98
Net Profit 413.80
Net Profit Margin (%) 18.73
Earnings Per Share (EPS) 14.66
EBITDA 623.11
Effective Tax Rate (%) 26.03
Particulars SEP 2024 (Values in Cr)
Revenue 2594.89
Operating Expense 1924.12
Net Profit 595.06
Net Profit Margin (%) 22.93
Earnings Per Share (EPS) 21.09
EBITDA 861.70
Effective Tax Rate (%) 25.15
Particulars JUN 2024 (Values in Cr)
Revenue 2296.88
Operating Expense 1766.87
Net Profit 453.73
Net Profit Margin (%) 19.75
Earnings Per Share (EPS) 16.08
EBITDA 686.75
Effective Tax Rate (%) 26.61
Particulars MAR 2024 (Values in Cr)
Revenue 2077.13
Operating Expense 1786.57
Net Profit 4613.70
Net Profit Margin (%) 222.11
Earnings Per Share (EPS) 163.50
EBITDA 6430.64
Effective Tax Rate (%) 26.70
Particulars DEC 2023 (Values in Cr)
Revenue 1304.16
Operating Expense 1674.12
Net Profit -20.41
Net Profit Margin (%) -1.56
Earnings Per Share (EPS) -0.72
EBITDA 49.25
Effective Tax Rate (%) 72.96
Particulars MAR 2024 (Values in Cr)
Revenue 7649.76
Operating Expense 7128.73
Net Profit 5167.29
Net Profit Margin (%) 67.54
Earnings Per Share (EPS) 183.13
EBITDA 7480.01
Effective Tax Rate (%) 26.18
Particulars MAR 2023 (Values in Cr)
Revenue 8019.67
Operating Expense 7138.86
Net Profit 1208.77
Net Profit Margin (%) 15.07
Earnings Per Share (EPS) 42.84
EBITDA 1962.84
Effective Tax Rate (%) 23.10
Particulars MAR 2022 (Values in Cr)
Revenue 8017.38
Operating Expense 6849.10
Net Profit 1997.79
Net Profit Margin (%) 24.91
Earnings Per Share (EPS) 70.80
EBITDA 2733.18
Effective Tax Rate (%) 14.53
Particulars MAR 2021 (Values in Cr)
Revenue 7450.91
Operating Expense 6094.30
Net Profit 1649.45
Net Profit Margin (%) 22.13
Earnings Per Share (EPS) 58.46
EBITDA 2360.48
Effective Tax Rate (%) 15.14
Particulars MAR 2020 (Values in Cr)
Revenue 6491.20
Operating Expense 5803.33
Net Profit 1354.55
Net Profit Margin (%) 20.86
Earnings Per Share (EPS) 48.00
EBITDA 1929.57
Effective Tax Rate (%) 11.73
Particulars MAR 2024 (Values in Cr)
Book Value / Share 278.11
ROE % -50.87
ROCE % 12.05
Total Debt to Total Equity 0.34
EBITDA Margin 17.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 335.75
ROE % 7.43
ROCE % 9.75
Total Debt to Total Equity 0.46
EBITDA Margin 16.56
Particulars MAR 2022 (Values in Cr)
Book Value / Share 322.03
ROE % 14.36
ROCE % 15.77
Total Debt to Total Equity 0.55
EBITDA Margin 20.26
Particulars MAR 2021 (Values in Cr)
Book Value / Share 250.37
ROE % 14.77
ROCE % 14.70
Total Debt to Total Equity 0.75
EBITDA Margin 19.91
Particulars MAR 2020 (Values in Cr)
Book Value / Share 215.14
ROE % 13.29
ROCE % 13.70
Total Debt to Total Equity 0.80
EBITDA Margin 17.77
Particulars MAR 2024 (Values in Cr)
Book Value / Share 814.01
ROE % 6.98
ROCE % 9.75
Total Debt to Total Equity 0.10
EBITDA Margin 30.54
Particulars MAR 2023 (Values in Cr)
Book Value / Share 633.57
ROE % 9.12
ROCE % 10.79
Total Debt to Total Equity 0.20
EBITDA Margin 29.84
Particulars MAR 2022 (Values in Cr)
Book Value / Share 593.21
ROE % 10.42
ROCE % 10.93
Total Debt to Total Equity 0.24
EBITDA Margin 28.29
Particulars MAR 2021 (Values in Cr)
Book Value / Share 524.84
ROE % 11.77
ROCE % 12.39
Total Debt to Total Equity 0.26
EBITDA Margin 31.19
Particulars MAR 2020 (Values in Cr)
Book Value / Share 468.73
ROE % 10.76
ROCE % 11.13
Total Debt to Total Equity 0.27
EBITDA Margin 28.75
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1659.45
Total Assets 14358.62
Total Liabilities 14358.62
Total Equity 7847.54
Share Outstanding 282188156
Price to Book Ratio 1.18
Return on Assets (%) -10.45
Return on Capital (%) -16.99
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1160.29
Total Assets 19371.67
Total Liabilities 19371.67
Total Equity 9839.25
Share Outstanding 282168156
Price to Book Ratio 0.73
Return on Assets (%) 1.53
Return on Capital (%) 2.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1411.51
Total Assets 17083.28
Total Liabilities 17083.28
Total Equity 9438.12
Share Outstanding 282168156
Price to Book Ratio 0.75
Return on Assets (%) 5.51
Return on Capital (%) 7.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1139.15
Total Assets 15603.57
Total Liabilities 15603.57
Total Equity 7064.27
Share Outstanding 282168156
Price to Book Ratio 0.89
Return on Assets (%) 6.21
Return on Capital (%) 8.25
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1111.24
Total Assets 14684.80
Total Liabilities 14684.80
Total Equity 6070.11
Share Outstanding 282168156
Price to Book Ratio 0.44
Return on Assets (%) 5.28
Return on Capital (%) 7.35
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 129.15
Total Assets 27414.39
Total Liabilities 27414.39
Total Equity 22970.62
Share Outstanding 282188156
Price to Book Ratio 1.18
Return on Assets (%) 18.84
Return on Capital (%) 21.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 93.79
Total Assets 24585.92
Total Liabilities 24585.92
Total Equity 17877.46
Share Outstanding 282168156
Price to Book Ratio 0.73
Return on Assets (%) 4.91
Return on Capital (%) 5.75
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 29.63
Total Assets 22914.48
Total Liabilities 22914.48
Total Equity 16738.58
Share Outstanding 282168156
Price to Book Ratio 0.75
Return on Assets (%) 8.71
Return on Capital (%) 9.79
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 15.78
Total Assets 20617.52
Total Liabilities 20617.52
Total Equity 14809.50
Share Outstanding 282168156
Price to Book Ratio 0.89
Return on Assets (%) 8.00
Return on Capital (%) 8.95
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 88.25
Total Assets 18951.59
Total Liabilities 18951.59
Total Equity 13226.26
Share Outstanding 282168156
Price to Book Ratio 0.44
Return on Assets (%) 7.14
Return on Capital (%) 8.06
Particulars MAR 2024 (Values in Cr)
Net Income 569.18
Cash from Operations 782.04
Cash from Investing 4560.89
Cash from Financing -3906.12
Net change in Cash 389.32
Free Cash Flow 1680.42
Particulars MAR 2023 (Values in Cr)
Net Income 868.45
Cash from Operations 1265.93
Cash from Investing -528.49
Cash from Financing -77.45
Net change in Cash 19.44
Free Cash Flow 1873.69
Particulars MAR 2022 (Values in Cr)
Net Income 1441.24
Cash from Operations 1667.09
Cash from Investing -333.28
Cash from Financing -520.49
Net change in Cash 254.88
Free Cash Flow 2457.21
Particulars MAR 2021 (Values in Cr)
Net Income 1382.47
Cash from Operations 1641.45
Cash from Investing -675.23
Cash from Financing -441.77
Net change in Cash 14.19
Free Cash Flow 2416.21
Particulars MAR 2020 (Values in Cr)
Net Income 1096.07
Cash from Operations 1859.36
Cash from Investing -783.51
Cash from Financing -444.66
Net change in Cash 173.99
Free Cash Flow 2791.78
Particulars MAR 2024 (Values in Cr)
Net Income 7000.74
Cash from Operations 375.64
Cash from Investing 3197.19
Cash from Financing -2666.44
Net change in Cash 35.29
Free Cash Flow 570.76
Particulars MAR 2023 (Values in Cr)
Net Income 1571.87
Cash from Operations 1890.48
Cash from Investing -431.46
Cash from Financing -978.49
Net change in Cash 64.09
Free Cash Flow 2080.10
Particulars MAR 2022 (Values in Cr)
Net Income 2337.44
Cash from Operations 1606.78
Cash from Investing -896.92
Cash from Financing -305.12
Net change in Cash 14.02
Free Cash Flow 1770.13
Particulars MAR 2021 (Values in Cr)
Net Income 1943.75
Cash from Operations 1579.25
Cash from Investing -1235.23
Cash from Financing -80.79
Net change in Cash -72.60
Free Cash Flow 1790.72
Particulars MAR 2020 (Values in Cr)
Net Income 1534.64
Cash from Operations 1918.46
Cash from Investing -1607.38
Cash from Financing -139.41
Net change in Cash -167.68
Free Cash Flow 2037.66
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

GLENMARK PHARMACEUTICALS Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1381.20 -0.23 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 1387.60
  • 26 Days 1412.20
  • 10 Days 1393.20
  • 50 Days 1427.70
  • 12 Days 1396.40
  • 100 Days 1453.60
  • 20 Days 1407.20
  • 200 Days 1424.50
1393.63 PIVOT

First Support

1370.77

First Resistance

1407.27

Second Support

1357.13

Second Resistance

1430.13

Third Support

1334.27

Third Resistance

1443.77

RSI

45.09

ADX

17.41

MACD

-15.84

Williams % R

-67.91

Commodity Channel Index (CCI)

-48.11

Date

2025-04-30

Week

471749.00

Same Day

453710.00

Month

425207.00

1 Year

0.97

3 Year

0.94

Over 1 Month

-8.48%

down

Over 1 Year

30.64%

down

Over 3 Months

-4.66%

down

Over 3 Years

46.70%

down

Over 6 Months

-17.29%

down

Over 5 Years

32.59%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

GLENMARK PHARMACEUTICALS shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
15.59%
Promoter Holdings
46.64%
FII
23.15%
DII
14.6%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category

News

Left Arrow
Right Arrow

GLENMARK PHARMACEUTICALS corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
18 Sep 2023 2.5 Final 19 Sep 2023 Equity shares
12 Sep 2022 2.5 Final 14 Sep 2022 Equity shares
08 Sep 2021 2.5 Final 10 Sep 2021 Equity shares
17 Sep 2020 2.5 Final 19 Sep 2020 Equity shares
19 Sep 2019 2.0 Final 21 Sep 2019 Equity shares
19 Sep 2018 2.0 Final 22 Sep 2018 Equity shares
20 Sep 2017 2.0 Final 22 Sep 2017 Equity shares
03 Aug 2016 2.0 Final 05 Aug 2016 Equity shares
10 Sep 2015 2.0 Final 14 Sep 2015 Equity shares
10 Jul 2014 2.0 Final 14 Jul 2014 Equity shares
18 Jul 2013 2.0 Final 22 Jul 2013 Equity shares
19 Jul 2012 2.0 Final 23 Jul 2012 Equity shares
28 Jul 2011 0.4 Final 01 Aug 2011 Equity shares
16 Sep 2010 0.4 Final 20 Sep 2010 Equity shares
10 Sep 2009 0.4 Final 14 Sep 2009 Equity shares
07 Nov 2007 1.4 Interim 08 Nov 2007 Equity shares
04 Jan 2007 0.8 Interim 05 Jan 2007 Equity shares
27 Apr 2005 0.0 Interim 02 May 2005 Equity shares
Ex-Date Ex-Bonus Ratio
08 Mar 2005 04 Mar 2005 1:1
Ex-Date Old FV NEW FV Record Date
10 Sep 2007 2.0 1.0 17 Sep 2007
23 Oct 2003 10.0 2.0 31 Oct 2003
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
18 Sep 2023 2.5 Final 19 Sep 2023 Equity shares
12 Sep 2022 2.5 Final 14 Sep 2022 Equity shares
08 Sep 2021 2.5 Final 10 Sep 2021 Equity shares
17 Sep 2020 2.5 Final 19 Sep 2020 Equity shares
19 Sep 2019 2.0 Final 21 Sep 2019 Equity shares
19 Sep 2018 2.0 Final 22 Sep 2018 Equity shares
20 Sep 2017 2.0 Final 22 Sep 2017 Equity shares
03 Aug 2016 2.0 Final 05 Aug 2016 Equity shares
10 Sep 2015 2.0 Final 14 Sep 2015 Equity shares
10 Jul 2014 2.0 Final 14 Jul 2014 Equity shares
18 Jul 2013 2.0 Final 22 Jul 2013 Equity shares
19 Jul 2012 2.0 Final 23 Jul 2012 Equity shares
28 Jul 2011 0.4 Final 01 Aug 2011 Equity shares
16 Sep 2010 0.4 Final 20 Sep 2010 Equity shares
10 Sep 2009 0.4 Final 14 Sep 2009 Equity shares
07 Nov 2007 1.4 Interim 08 Nov 2007 Equity shares
04 Jan 2007 0.8 Interim 05 Jan 2007 Equity shares
27 Apr 2005 0.0 Interim 02 May 2005 Equity shares
Ex-Date Ex-Bonus Ratio
08 Mar 2005 04 Mar 2005 1:1
Ex-Date Old FV NEW FV Record Date
10 Sep 2007 2.0 1.0 17 Sep 2007
23 Oct 2003 10.0 2.0 31 Oct 2003

Glenmark Share Result Highlights

ParticularsSep 2024 (Values in Cr)Jun 2024 (Values in Cr)Mar 2024 (Values in Cr)Sep 2023 (Values in Cr)
Revenue₹2594.89₹2296.88₹7649.76₹2170.40
Operating Expense₹1924.12₹1766.87₹7128.73₹1897.96
Net Profit₹595.06₹453.73₹5167.29₹302.35
Net Profit Margin22.93%19.75%67.54%13.93%
Earnings Per Share₹21.09₹16.08₹183.13₹10.72
EBITDA₹861.70₹686.75₹7480.01₹497.41
Effective Tax Rate25.15%26.61%26.18%22.34%

Key Highlights

  • Glenmark Pharmaceuticals has shown consistent growth in revenue and net profit, with a net profit margin of 22.93% for Q2 FY 2024.
  • The company reported an EBITDA of ₹861.70 Cr, indicating healthy operational performance.
  • Earnings Per Share (EPS) surged to ₹21.09 in Q2, demonstrating improved shareholder value.
  • The positive performance has contributed to the growth of the Glenmark Share Price, reflecting the company's solid financial health and potential for future returns.

Glenmark Share Annual Reports

ParticularsMar 2024 (Values in Cr)
Revenue₹7649.76
Operating Expense₹7128.73
Net Profit₹5167.29
Net Profit Margin67.54%
Earnings Per Share₹183.13
EBITDA₹7480.01
Effective Tax Rate26.18%

Key Highlights

  • Despite challenges in Dec 2023, Glenmark Pharmaceuticals showed an impressive turnaround by FY 2024, with revenue increasing to ₹7649.76 Cr.
  • The company posted a net profit of ₹5167.29 Cr in Mar 2024, marking a net profit margin of 67.54%, a significant recovery from the loss in Dec 2023.
  • The Earnings Per Share (EPS) improved dramatically to ₹183.13 in FY 2024, demonstrating robust growth in profitability, which positively influenced the Glenmark Share Price.

Glenmark Share Dividend

Ex-DateDividend Amount (₹)Dividend TypeRecord DateInstrument Type
18 Sep, 20232.5Final19 Sep, 2023Equity shares

Key Highlights

  • Consistent Payouts: Glenmark has issued both final and interim dividends over the years, demonstrating its financial strength and commitment to rewarding shareholders.
  • Recent Final Dividends: The company’s most recent final dividend of ₹2.5 per share was paid in 2023, following similar payouts in previous years.
  • Interim Dividends: Notably, Glenmark has also declared interim dividends, such as ₹1.4 in 2007 and ₹0.8 in 2007, showcasing its willingness to distribute earnings when appropriate during the year.
  • Shareholder Confidence: Both types of dividends illustrate the company's ongoing efforts to maintain investor confidence by sharing profits regularly, which positively impacts the Glenmark Share Price.

Popular FAQs

1. Who is the CEO of Glenmark Pharmaceuticals Ltd?

The current CEO of Glenmark Pharmaceuticals Ltd is Glenn Saldanha, who is also the Chairman and Managing Director of the company. He has been a key figure in shaping the growth and success of Glenmark since its inception in 1977, leading its transformation into a global pharmaceutical player.

 

2. When was Glenmark Pharmaceuticals Ltd established?

Glenmark Pharmaceuticals Ltd was established on November 18, 1977. Since then, it has grown significantly, expanding its operations in various therapeutic areas and becoming a prominent player in the global pharmaceutical industry.

 

3. What factors influence the Glenmark Share Price?

Several factors influence the Glenmark share price, including the company's financial performance, new product launches, regulatory approvals, global market expansion, and developments in their R&D pipeline, particularly in the oncology, respiratory, and dermatology sectors. Market sentiment and broader economic conditions also play a critical role.

 

4. Is Glenmark Pharmaceuticals Ltd debt-free?

No, Glenmark Pharmaceuticals Ltd is not completely debt-free. As of March 2024, its consolidated debt stands at INR 9.9 billion, a reduction from higher amounts in previous years. The company is actively working towards prepaying most of its long-term debt using proceeds from the sale of its API business while maintaining a solid liquidity profile.

 

5. What is the CAGR of Glenmark Share?

The Compound Annual Growth Rate (CAGR) of Glenmark share price is as follows:

  • 10 Years: 7%
  • 5 Years: 37%
  • 3 Years: 46%
  • 1 Year: 95%

This reflects significant growth in recent years, particularly driven by strong performance in key therapeutic areas.

 

6. How has the Glenmark Share Price performed over the past year?

The Glenmark share price has surged by approximately 95.23% over the past year, with a 52-week high of ₹1,830.05 and a low of ₹764.25. While the stock has experienced slight declines in recent months—with returns of -10.65% over the past three months and -8.45% over the last month—the overall long-term outlook remains positive, with analysts giving it a "Buy" rating.

GLENMARK PHARMACEUTICALS Share Price

Glenmark Pharmaceuticals Ltd was incorporated in November 18th, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.

The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology. Its branded generics business has a significant presence in markets across emerging economies including India. The company has 14 manufacturing facilities across US, India, Argentina, Czech Republic and Switzerland. The generics business services the requirements of developed markets like the US and Western Europe. The API business sells products in over 80 countries including the US, various countries in the EU, South America and India.

In the year 1979, the company entered dermatology market with the launch of 'Candid Cream'. In the year 1980, they started exporting their products. In the year 1983, the company commissioned their first manufacturing facility at Nasik in Maharashtra. In the year 1984, they established R&D department at Nasik Plant. In the year 1987, they launched Ascoril.

In the year 1989, the company started operations in Afghanistan, Sri Lanka, Kenya and Mauritius. In the year 1982, the company expanded the Nashik plant by acquiring the adjacent plot to include the R&D Department as well as increase in installed production capacity. In the year 1996, the company incorporated a wholly owned subsidiary company namely, Glenmark Exports Pvt Ltd to consolidate their position in international business. In the year 1999, they started marketing their products in Brazil. In the year 2000, they came out with the public issue. They entered in diabetes segment. Also, they acquired three brands from Lyka Labs.

In the year 2001, the company launched API manufacturing business. In the year 2002, they acquired an API manufacturing facility at Ankleshwar, Gujarat from Glaxosmithkline Pharmaceuticals Ltd. In the year 2004, the company entered their first out-licensing deal for discovery R&D with Forest Laboratories for Oglemilast, their CIPD/asthma molecule. They acquired Laboratories Klinger; Brazil together with their ANVISA approved manufacturing facility inorder to expand their operations in the Latin American markets. They commissioned their own manufacturing facility in Goa to service exports to regulated markets, namely USA.

In the year 2005, the company launched commercial sales front-end in the US. They commissioned a new manufacturing facility at Baddi, Himachal Pradesh. They entered collaborative agreement on Oglemilast with Teijin Pharma for the Japan region. Also, they announced collaborative agreement with Napa Pharmaceuticals Inc, for their anti-diarrheas compound Crofelemer. The company acquired Servycal S A, a marketing company in Argentina with strengths in oncology. Also, they acquired Bouwer Bartlett Pty Ltd, a sales and marketing company in South Africa.

In the year 2006, the company signed out-licensing deal in discovery R&D with Merck KGaA, Germany for their diabetes molecule, Melogliptin. Their lead molecule Oglemilast (GRC 3886) entered Phase II clinical trials. In the year 2007, the company acquired Medicamenta, a marketing and manufacturing company in the Czech Republic. Their molecule GRC 6211 for the potential treatment of pain, including osteo-arthritis pain out-licensed to Eli Lily. They received MHRA, UK approval for their semi-solid manufacturing plant at Baddi.

In the year 2008, the company initiated Phase II-b for Oglemilast (GRC 3886) in Asthma. They completed pre-clinical development for initiating Phase I trials for GBR 500, a monoclonal antibody for inflammation. The company's molecule for Rheumatoid Arthritis, GRC 4039, entered Phase I trials. They re-organized their business and incorporated Glenmark Genrics Ltd as a subsidiary company. They received USFDA approval for the state-or-the-art semi-solids manufacturing plant at Baddi. In the year 2009, the company's molecule for neurophatic pain, osteoarthritis, completed the Phase I trials. During the year 2009-10, the company incorporated a subsidiary company, namely Glenmark Generics B.V., Netherlands.

In the year 2010, Crofelemer, a first-in-class anti-diarrhoeal molecule completed phase 3 trials. They received the final approval for Pramipexole Dihydrochloride tablets from the USFDA. Glenmark Generics entered into an exclusive licensing agreement with Par Pharmaceuticals, USA to market Ezetimibe. The company and Sanofi-Aventis signed license agreement to grant Sanofi-Aventis a license for the development and commercialization of novel agents to treat chronic pain. They launched 'Prasugrel', a revolutionary new anti-platelet drug for the management of Acure Coronary Syndrome with PCT (Precutaneous Coronary Intervention) for the first time in India.

During the year 2010-11, the company has incorporated a subsidiary company namely, Glenmark Arzneimittel GmbH, Germany. In October 2010, the company won the Frost and Sullivan Award for 'Indian Innovator Pharmaceutical Company of the year' in October 2010. The company was chosen as the 'Best Company Across Emerging Markets' 2011, and recognized for the 'Best Overall Pipeline' 2011 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world.

In 2012, Forest Laboratories and Glenmark Signed Development Agreement for Worldwide Collaboration on Novel Agents to treat Chronic Inflammatory Conditions. Glenmark Generics announces the settlement of Paragraph IV litigation with Janssen Pharmaceuticals, Inc. Glenmark Generics receives tentative approval for zolmitriptan orally disintegrating tablets. The International Centre for Dispute Resolution ruled in favor of Glenmark on arbitration claim against Napo.

In 2013, Glenmark announces launch of Hydrocortisone Butyrate cream in the US. Glenmark announces a new Discovery and the Initiation of IND enabling studies of a novel monoclonal antibody targeting OX40. The USFDA approves the companies Crofelemer 125 mg delayed-release tablets for the symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy (ART). Glenmark Generics receives ANDA approval for Mupirocin Calcium Cream USP 2%. Atovaquone Prognanil (Malarone) patent revoked & Glenmark launches first UK generic. Glenmark discovers IND enabling studies of a novel monoclonal antibody.

In 2014, Glenmark merge its subsidiaries i.e. Glenmark Generics Ltd. ('GGL') and Glenmark Access Ltd. ('GAL') with GPL. Glenmark enters Oncology with the Discovery and the Initiation of IND enabling studies of an innovative bi-specific antibody. Glenmark Pharmaceuticals inaugurates new Antibody Manufacturing Facility in La Chaux-de-Fonds, Switzerland. US Food & Drug Administration (USFDA) has granted Glenmark its final acceptance for abbreviated new drug approval (ANDA) to the company. Glenmark Pharma receives $5 mn from Sanofi as milestone payment from Sanofi on a collaboration of its VLA2 (alpha2-beta l) integrin monoclonal antibody. Glenmark Generics gets USFDA nod for skin infection cream.

In 2015, Glenmark Pharmaceuticals Ltd announces approval and launch of Ashlyna TM Extended - Cycle Oral Contraceptive Tablets in the US. Glenmark Pharmaceuticals Ltd announces approval and launch of Trandolapril & Verapamil Hydrochloride (HCI). Glenmark Pharma gets US FDA nod for Salmecort MDI Inhaler in Russia. The Cabinet Committee on Economic Affairs (CCEA) headed by PM approves the foreign investment proposals of two pharma majors Glenmark Pharmaceuticals and Aurobindo Pharma worth Rs 4,187 crore. Glenmark Pharmaceuticals Ltd. has certified approving the Scheme of Arrangement of Glenmark Generics Ltd. and Glenmark Access Ltd. with Glenmark Pharmaceuticals Ltd. Glenmark announces Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe. Glenmark Pharmaceuticals receives tentative ANDA approval for Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg. Glenmark Pharmaceuticals receives ANDA approval for Clotrimazole and Betamethasone Dipropionate Cream USP, 1%: 0.05%. Glenmark Pharmaceuticals has entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd., and Royalty Pharma. During the year, the company received approval for generic Seretide in Russia.

On 19 September 2016, Glenmark Pharmaceuticals, Inc., USA announced that it has entered into a strategic Development, License and Commercialization Agreement with Particle Sciences, Inc. to develop and market a generic version of Celgene's ABRAXANE product - paclitaxel protein (albumin)-bound particles for injectable suspension. As per the terms of the agreement, Glenmark has obtained Global Exclusive Marketing and Distribution rights of the product upon commercialization. Particle Sciences will develop this product exclusively for Glenmark, and shall receive certain milestone payments during various stages of the product's development from Glenmark, including royalties on sales.

On 12 December 2016, Glenmark Pharmaceuticals Inc., USA announced the availability of ezetimibe, the first and only generic version of ZETIA (Merck) in the United States for the treatment of high cholesterol. The availability of ezetimibe is the result of a licensing partnership with Par Pharmaceutical, an Endo International plc operating company, with whom Glenmark will share profits. Glenmark and its partner, Endo will be entitled to 180 days of generic drug exclusivity for ezetimibe as provided for under Section 505 (j) (5) (B) (iv) of the FD&C Act.

On 19 December 2016, Glenmark Pharmaceuticals announced its strategic blueprint to transition into an innovation-led global pharmaceutical organization over the next decade. The Blueprint conveys the company's greater business alignment expanding generics to prioritizing research and development efforts in three key therapeutic areas: oncology, respiratory and dermatology. The innovative oncology pipeline, with candidates targeting multiple tumors, is the top priority with the greater promise to deliver novel, first-in-class molecules and help Glenmark evolve into a fully commercialized, innovation-led pharmaceutical company. The strategic blueprint also outlines aggressive plans to increase Glenmark's presence worldwide by strengthening focus on complex generics including injectables and expanding its manufacturing footprint.

On 2 March 2017, Glenmark Pharmaceuticals announced that its US subsidiary Glenmark Pharmaceuticals Inc., USA, and Evestra, Inc. have completed a strategic development, license and commercialization agreement to develop and market a generic version of Merck's & Co.'s NuvaRing product - etonogestrel/ethinyl estradiol vaginal ring - designed to allow women access to a more affordable birth control option. Development on the vaginal ring product is currently under way and the two companies expect to file an Abbreviated New Drug Application (ANDA) in fiscal 2019. Evestra will develop this product exclusively for Glenmark for the US market, and will receive certain milestone payments during various stages of the product's development, including royalties on net sales. Glenmark has secured exclusive marketing and distribution rights for the product, including an option to commercialize two additional Evestra vaginal ring products, for the US market.

On 30 March 2017, Glenmark Pharmaceuticals announced positive results for GSP 301, an investigational fixed-dose combination of mometasone furoate (25 mcg) and olopatadine hydrochloride (665 mcg) administered twice daily as a nasal spray being studied for the treatment of seasonal allergic rhinitis. These results are from a recently completed Phase 3 trial assessing the efficacy and safety of GSP 301 combination therapy versus mometasone, olopatadine or placebo.

On 14 December 2017, Glenmark Pharmaceuticals announced that it met its primary clinical endpoint in a Phase 3 study evaluating the safety of Ryaltris, an investigational fixed-dose combination nasal spray, in perennial allergic rhinitis (PAR). Ryaltris has conditionally accepted as the brand name for GSP 301 Nasal Spray by the US Food & Drug Administration (FDA). Glenmark plans to submit the company's first new drug application (NDA) to the FDA for Ryaltris for the treatment of patients with seasonal allergic rhinitis (SAR) in the first quarter of CY 2018.

On 22 February 2018, Glenmark Pharmaceuticals announced that it has entered into an exclusive agreement with South Korea's Sam Chun Dang Pharm. Co. Ltd. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the US and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America.

On 4 April 2018, Glenmark Pharmaceuticals and Helsinn Group (Helsinn), a Swiss pharmaceutical group focused on building quality cancer care products, announced that they have entered into an exclusive licensing agreement to introduce AKYNZEO in India and Nepal. AKYNZEO, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg in capsule form, is used for prevention of Chemotherapy-induced Nausea and Vomiting (CINV). The licensing agreement with Glenmark for AKYNZEO represents Helsinn's first such agreement in India. Glenmark will have exclusive marketing rights for AKYNZEO in India and Nepal.

On 22 May 2018, Glenmark Pharmaceuticals announced that the company has submitted a New Drug Application (NDA) to the US Food & Drug Administration (FDA) for its leading respiratory pipeline candidate Ryaltris, an investigational fixed-dose combination nasal spray of an antihistamine and a steroid, as a treatment for seasonal allergic rhinitis (SAR) in patients 12 years of age and older. Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg), formerly GSP 301 Nasal Spray, has been conditionally accepted by the FDA as the brand name.

On 19 June 2018, Glenmark Pharmaceuticals announced that the US Food & Drug Administration provided its first supplemental Abbreviated New Drug Applications (ANDA) approval for the company's manufacturing facility in Monroe, North Carolina. The approval covers: Atovaquone and Proguanil Hydrochloride Tablets, 250 MG/100 MG and 62.5 MG/25 MG, a generic version of GlaxoSmithKline's Malarone (atovaquone and proguanil hydrochloride) Tablets. The Monroe, North Carolina facility is Glenmark's first manufacturing site in the US, designed to manufacture a variety of fixed dose pharmaceutical formulations. Glenmark has invested more than $100 million into the facility with plans for further expansion in the coming years. At peak capacity, the site is anticipated to produce 300-400 million tablets and capsules, 20-25 million vials and pre-filled syringes and 25-30 million ampoules for inhaled formulations.

During the F.Y. 2017-18 Glenmark Pharmaceuticals Singapore Pte. Ltd. was formed as the wholly owned subsidiary of the company

In FY18, Glenmark was granted approval of 21 Abbreviated New Drug Applications (ANDA), comprising 18 final approvals and three tentative approvals. Notable approvals include Aprepitant Capsules USP, Atomoxetine Capsules USP, Nitroglycerin Sublingual Tablets and Propafenone Hydrochloride Extended-Release Capsules USP. The Company filed a total of 16 ANDA applications with the US FDA throughout the fiscal year.

During the year 2018, Glenmark launched Dermikelp, VWash Plus, Tacroz and Tacroz F in Zambia; Tacroz and Telma H in Tanzania; Ascoril D, Teneligliptin and its combination with Metformin in Mauritius, Momate F in Uganda and Sertaconazole (Onabet) in Sudan.

During the year 2018, Glenmark launched Tacroz, Dosetil and Momate NS in Philippines; Momate NS, Dermikelp and VWash in Malaysia and Konzert in Cambodia in the Asia region.

As on March 31 2018, the Company has filed over 370 Global DMFs in various markets, including 103 USDMFs, 28 CEPs, 40 EU- DMFs, 22 Canadian DMFs, 12 Japan DMFs, 13 Australian DMFs and other DMFs in various Rest-of-the-World (ROW) countries.

During the year 2018, NebZmart, NebZsol and Vocety were launched in Brazil. In Colombia, the Company strengthened its dermatology portfolio and introduced Glenpalene, Glenpalene C, Dermotil S, Glencort, Butemax and Clotridid. Momate AZ nasal spray was launched in the Caribbean region and Glenmark is the first generic alternative in the market offering this unique combination.

In FY18, Momate Rhino Advance, a unique combination of mometasone + azelastine nasal spray on the local market, was launched in Uzbekistan and is indicated for the treatment of patients with seasonal allergic rhinitis. Momat Rino 60 and 120 doses nasal sprays were also launched in Uzbekistan. During the year, Glenmark launched Glenspray (mometasone) 50 mcg/120 doses and Glenspray (mometasone) 50 mcg/60 doses in Ukraine.

During the year 2018, Glenmark also successfully concluded the US FDA audit of the API plant at Mohol and is awaiting the EIR from the agency.

During the year 2018-19, the Company acquired 100% stake in Zorg Laboratories Private Limited (Zorg) for an aggregate consideration of 5 lacs before adjustments and subject to legal and financial due diligence. Subsequently, name of Zorg was changed to Glenmark Life Sciences Limited (GLS). The shareholders of the Company approved the transfer of its Active Pharmaceuticals Business (API) to GLS by passing a resolution through postal ballot.

During the FY2019, the Company had entered into a collaboration with leading, home-grown private equity firm True North Enterprise Private Limited (True North') and transferred its Orthopaedic and Pain management business valued at Rs 635 crore to Integrace Private Limited, a subsidiary of True North. Integrace will market the product portfolio in India and Nepal.

As on 31 March 2019,the company has 42 subsidiary companies under its roof.

The Company filed a total of 13 ANDAs with the USFDA during the financial year. In FY 2018-19, Glenmark was granted approval for 25 Abbreviated New Drug Applications (ANDA), comprising of 20 final approvals and 5 tentative approvals.

During the year, the company bagged CII Safety Health and Environmental Excellence and Innovation Award 2018 for the Indore facility.

During the FY2020,the Company had entered into Business Transfer Agreement with Integrace Private Limited for transfer Company's Gynaecology business, valued at Rs 115 crore.

During the year, the Company entered into definitive agreement with Hindustan Unilever Limited for divestment of VWash franchise comprising VWash Plus Intimate Hygiene Wash, VWash WOW, VWash Plus Bikini Line, VWash Plus wipes and other such assets globally including the associated trademarks, brand names and certain business contracts.

It launched a globally researched innovator molecule, Remogliflozin in FY 2019.

As on 31 March 2020, the company has 44 subsidiary companies under roof. It introduced a fixed-dose combination of Remogliflozin Etabonate and Vildagliptin in 2020. It also launched a fixed-dose combination of Remogliflozin+Metformin under the brand names Remo-M and Remo-Zen M.

Glenmark Life Sciences Limited, a wholly owned subsidiary of the Company on 16th April 2021 has filed a draft red herring prospectus with the Securities and Exchange Board of India for an initial public offer, comprising of a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences Limited, by Glenmark Pharmaceuticals Limited. The !PO will be subject to market conditions, receipt of applicable approvals and other considerations.

In the fiscal year 2020-21, Glenmark was granted approval of 14 ANDAs comprised of 10 final approvals and 4 tentative approvals. Additionally, it was granted approval on a Prior Approval Supplement (PAS) for the 0.25 mg strength for Fingnolimod Capsules. Notable approvals include: Sirolimus Tablets, Tacrolimus Capsules USP, Topiramate Extended-Release Capsules USP, Chlorpromazine Hydrochloride Tablets USP and Diltiazem Hydrochloride Extended-Release Capsules USP. The Company filed a total of 7 ANDAs with the USFDA in FY21 and plan to file 18-20 ANDAs in FY22 including 5-6 filings which got delayed in FY21 due to the pandemic. During 2021, its subsidiary, Ichnos Sciences signed a licensing agreement with Almirall SA for the IL-1RAP antagonist ISB 880 for an upfront payment of EUR 20.8 Million. It received approval for 14 ANDAs that comprised 10 final approvals and 4 tentative approvals. It launched 10 new products in FY 2020-21. On 30th April, 2021, the Company made a strategic investment of Rs. 400 million in ABCD Technologies LLP .

During the year 2022, Company received US FDA's NDA approval for novel Ryaltris-AZ as a novel fixed dose with a steroid of Mometasone Furoate and Azelastine for the treatment of allergic rhinitis in adults and paediatric patients 12 years of age and older. It launched Tiotropium Bromide Dry Powder Inhaler (DPI) in UK. It launched Tavulus in Spain and Tiotropium in Germany. It also launched Beclometasone to provide asthma patients access to a high-quality, cost-effective inhaler. It launched Glendes in Malaysia for treatment of minor cases of allergy. In Brazil, it launched Salbutamol to relieve symptoms of asthma and chronic obstructive pulmonary disease (COPD) such as coughing, wheezing and feeling breathless. It launched Canditral- SB in India to treat fungal infections of the mouth, throat, toenails, fingernails or lungs. To treat the symptoms of LennoxGastaut Syndrome (seizures), it launched Rufinamide tablets in the USA. It collaborated with Canadian biotech firm SaNOtize Research & Development Corp. to manufacture, market and distribute its breakthrough Nitric Oxide Nasal Spray (NONS) for COVID-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam. It launched NONS under the brand name FabiSpray in February 2022, after receiving manufacturing and marketing approval from the Drugs Controller General of India (DCGI) as part of the accelerated approval process. Ichnos Sciences Inc., a subsidiary of Glenmark completed a EUR ~21 Million exclusive licensing agreement for the IL-1RAP antagonist ISB 880. Remogliflozin, Vildagliptin, Metformin, a Fixed Dose Combination (FDC) was launched during the year to enhance patient access to SGLT2 and DPP4 inhibitors for effective treatment of diabetes. FabiSpray was also launched in Singapore and Hong Kong under the brand name VirX. It introduced India's first Probiotic based product across its dermatology portfolio, such as Elovera Pro Cream and Elovera Pro Lotion. It launched 10 new products in the US taking total marketing portfolio in US 174 generic products authorized for distribution in the U.S. market. It entered into an agreement with AstraZeneca to commercialize its product, Pulmicort Respules in Colombia. Besides this, it entered into exclusive licensing agreement with Lotus International Pte. Ltd. for commercializing Ryaltris in Singapore, Hong Kong and Vietnam. Three new pharmaceutical modules became fully operational at its Ankleshwar facility.

During the year 2022-23, in the Respiratory segment, Glenmark became the first company in India to market Indamet - an innovative fixed drug combination of Indaceterol, a long-acting beta-agonist and mometasone, an inhaled corticosteroid, for the treatment of uncontrolled asthma. In the Diabetes segment, it launched sitagliptin under the brand name SITAZIT and its fixed dose combinations with metformin and dapagliflozin respectively; teneligliptin + pioglitazone Fixed-Dose Combination drug for Type 2 Diabetes under the brand name Zita Plus Pio; lobeglitazone 0.5mg, under the brand name LOBG; Fixed-Dose Combination (FDC) of Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) SR under the brand name Zita-PioMet; Lobeglitazone + Metformin under the brand name LOBG-M. In the Cardio-Vascular segment, it launched Sacubitril + Valsartan under the brand name, Sacu V for the treatment of heart failure. New products such as La Shield Pollution Protect, La Shield Probiotic Moisturizer and Scalpe Pro Shampoo contributed to business growth in FY23.

Thereafter, in FY23, Glenmark launched 8 new products during the fiscal year 2022-23, consisting of a mix of immediate-release oral solids and an injectable. Notable launches include Ezetimibe Tablets USP; Abiraterone Acetate Tablets USP, 500 mg; Fingolimod Capsules, 0.5 mg; Sodium Phenylbutyrate Tablets USP, 500 mg; Nicardipine Hydrochloride Capsules; Bumetanide Injection, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials; and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, and Teriflunomide Tablets. It launched first generics, Teriflunomide (Aubagio) Tablets. It got into a distribution agreement with Cediprof for USFDA approved Mixed Amphetamines Immediate-Release Tablets.

As of March 31, 2023, Glenmark's marketing portfolio included 183 generic products authorized for distribution in the U.S. market. 4 new products were introduced in the market, including Fenismart(dimetindene) gel and Phelisans (phenasone + lidocaine) ear drops. It launched RYALTRIS in the Malaysian market in 4Q of FY23.

Parent organization Indian Private
NSE symbol GLENMARK
Founded 1977
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Glenmark Pharmaceuticals Ltd?

Answer Field

The share price of Glenmark Pharmaceuticals Ltd for NSE is ₹ 1381.2 and for BSE is ₹ 1377.5.

What is the Market Cap of Glenmark Pharmaceuticals Ltd?

Answer Field

The market cap of Glenmark Pharmaceuticals Ltd for NSE is ₹ 3,89,75.83 Cr. and for BSE is ₹ 3,88,71.42 Cr. as of now.

What is the 52 Week High and Low of Glenmark Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Glenmark Pharmaceuticals Ltd for NSE is ₹ 1830.95 and ₹ 985.20 and for BSE is ₹ 1830.05 and ₹ 985.60.

How to Buy Glenmark Pharmaceuticals Ltd share?

Answer Field

You can trade in Glenmark Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Glenmark Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 30.64%.

What is the Current Share Price of Glenmark Pharmaceuticals Ltd?

Answer Field

Glenmark Pharmaceuticals Ltd share price is for NSE ₹ 1381.2 & for BSE ₹ 1377.5 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Glenmark Pharmaceuticals Ltd Share?

Answer Field

The market cap of Glenmark Pharmaceuticals Ltd for NSE ₹ 3,89,75.83 & for BSE ₹ 3,88,71.42 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Glenmark Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Glenmark Pharmaceuticals Ltd share is 6.41.

What is the PB ratio of Glenmark Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Glenmark Pharmaceuticals Ltd share is 848.58.

How to Buy Glenmark Pharmaceuticals Ltd Share?

Answer Field

You can trade in Glenmark Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Glenmark Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Glenmark Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Glenmark Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|